New drug cocktail shows promise for tough bile duct cancer
NCT ID NCT05170438
First seen Jun 25, 2026 · Last updated Jul 02, 2026 · Updated 2 times
Summary
This phase 2 trial tests a combination of two drugs, lenvatinib and paclitaxel, in 51 adults with advanced biliary tract cancer that has worsened after standard gemcitabine treatment. The goal is to see if the combo can shrink tumors and slow the disease. Participants take lenvatinib daily by mouth and receive paclitaxel through an IV three times per cycle.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- lenvatinib and paclitaxel
- What this could lead to
- If successful, this combination could offer a new treatment option for patients with advanced biliary tract cancer who have stopped responding to standard chemotherapy.
- What could go wrong
- This is a small, early-phase trial with only 51 participants, so results may not apply to all patients. The drugs can cause side effects like high blood pressure, fatigue, and nerve damage.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED BILIARY TRACT CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Chang Gung Memorial Hospital
Kaohsiung City, Taiwan
-
Chang Gung Memorial Hospital
Taoyuan, Taiwan
-
China Medical University Hospital
Taichung, Taiwan
-
Kaohsiung Medical University Chung-Ho Memorial Hospital
Kaohsiung City, Taiwan
-
MacKay Memorial Hospital
Taipei, Taiwan
-
National Cheng Kung University Hospital
Tainan, Taiwan
-
National Taiwan University Hospital
Taipei, Taiwan
-
Taipei Veterans General Hospital
Taipei, Taiwan
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can sound waves supercharge immunotherapy against bile duct cancer?
- Can blood tests reveal how liver and bile duct cancers respond to treatment?
- Can a One-Two punch of heat and drainage tame inoperable bile duct cancer?
- Can a pill target Hard-to-Treat bile duct cancers? a new drug puts FGFR2 mutations to the test
- Can matching drugs to tumor genes beat biliary cancer?
- Can freezing tumors boost immunotherapy in hard-to-treat bile duct cancers?